AIM OF THE STUDY: To assess wildlife for sale for medicinal purposes, and document their medicinal use at Kyaiktiyo, a pilgrimage site at a 1100m tall mountain, with many of the pilgrims climbing to the top. In addition we address legal issues relating to the production and sale of traditional medicine that contain legally protected animals.
MATERIAL AND METHODS: Four visits were made to Kyaiktiyo, Myanmar, between 2000 and 2017 to quantify animal parts on display and through discussions with vendors to obtain information on medicinal use of these parts.
RESULTS: Twenty-three species, mostly mammals, were recorded to be used for traditional medicine. The most common were Chinese serow Capricornis milneedwardsii, Asian elephant Elephas maximus, and Asiatic black bear Ursus thibetanus. Over 600 bodies or body parts were present. Combined, these parts purportedly provided cures or relief for at least 15 ailments or diseases. The most commonly mentioned treatment was that of using rendered animal fats/oils externally to relieve/cure aching joints or muscles. This treatment allegedly provides instant relief to pilgrims after an arduous climb up the mountain. Purported cures for various skin diseases was the next common use for the animal species on offer. Ten of the species observed for sale at Kyaiktiyo are listed as globally threatened, and 15 are protected and cannot be legally traded. Ambiguities in Myanmar's legislation mean that protected animals or their body parts cannot be traded, however traditional medicines can be made out of them provided rules relating to the manufacturing of traditional medicines are adhered to.
CONCLUSION: This study indicated that animals and their parts continue to be openly offered for sale at Kyaiktiyo to treat various illnesses. Despite these products potential medical, traditional or cultural importance, solutions have to been found on how to ensure that, in line with Myanmar's laws, use of traditional local medicine does not impede the conservation of imperilled species.
AIM OF THE STUDY: To evaluate the anti-proliferative activity of local medicinal plant species Clausena lansium Skeels, Clinacanthus nutans (Burm. f.) Lindau, Leea indica (Burm. f.) Merr., Pereskia bleo (Kunth) DC., Strobilanthes crispus (L.) Blume, Vernonia amygdalina Delile and Vitex trifolia L.
MATERIALS AND METHOD: Fresh, healthy and mature leaves of the seven medicinal plants were harvested from various locations in Singapore and Malaysia for Soxhlet, ultrasonication and maceration extractions in three different solvents (water, ethanol and methanol). Cell proliferation assay using water soluble tetrazolium salt (WST-1) assay was performed on twelve human cancer cell lines derived from breast (MDA-MB-231, T47D), cervical (C33A), colon (HCT116), leukemia (U937), liver (HepG2, SNU-182, SNU-449), ovarian (OVCAR-5, PA-1, SK-OV-3) and uterine (MES-SA/DX5) cancer.
RESULTS: A total of 37 fresh leaf extracts from seven medicinal plants were evaluated for their anti-tumour activities in twelve human cancer cell lines. Of these, the extracts of C. lansium, L. indica, P. bleo, S. crispus, V. amygdalina and V. trifolia exhibited promising anti-proliferative activity against multiple cancer cell lines. Further investigation of selected promising leaf extracts indicated that maceration methanolic extract of L. indica was most effective overall against majority of the cancer cell lines, with best IC50 values of 31.5 ± 11.4 µg/mL, 37.5 ± 0.7 µg/mL and 43.0 ± 6.2 µg/mL in cervical C33A, liver SNU-449, and ovarian PA-1 cancer cell lines, respectively.
CONCLUSION: The results of this study provide new scientific evidence for the traditional use of local medicinal plant species C. lansium, L . indica, P. bleo, S. crispus, V. amygdalina and V. trifolia in cancer treatment. These results highlight the importance of the upkeep of these indigenous plants in modern society and their relevance as resources for drug discovery.